<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-22-12-2025-shutterstock_2141875239-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/PT-22-12-2025-shutterstock_2141875239-430x241.jpg"/>
                                    
                                    <figcaption>Novartis is advancing plans for new radioligand therapy manufacturing facilities in Texas and Florida. Credit: JHVEPhoto/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and supporting continued investment in manufacturing, and research and development in the US.</p>



<p>Under the agreement, Novartis has voluntarily committed to several actions. These include launching future medicines with prices comparable to those in other high-income countries; establishing direct-to-patient platforms for Tabrecta (capmatinib), Mayzent (siponimod), and Rydapt (midostaurin), with these platforms being accessible via TrumpRx.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Immuno-oncology (IO) - Thematic Intelligence </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Novartis AG - Digital Transformation Strategies </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Novartis will seek participation in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model to further improve access to medicines for Medicaid patients.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>The company will also support efforts to address the global imbalance in pharmaceutical innovation investment.</p>



<p>Novartis CEO Vas Narasimhan said: “This agreement continues our long-term partnership with the US government to advance the development and manufacturing of breakthrough treatments for patients in the United States.</p>



<p>“We are committed to working with governments worldwide to ensure innovation is appropriately valued and that our medicines reach the patients who need them most.”</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Earlier this year, Novartis announced plans to invest $23bn over five years to expand its US research and manufacturing infrastructure.</p>



<p>Following this announcement, the company revealed plans for a $1.1bn biomedical research centre in San Diego, initiated construction of a flagship manufacturing hub with three facilities in the Raleigh/Durham area of North Carolina, and opened a radioligand therapy manufacturing plant in Carlsbad, California.</p><div id="slot-two"></div>



<p>Additionally, Novartis is advancing plans for new radioligand therapy manufacturing facilities in Texas and Florida. As a result of these investments, the company anticipates receiving three years of tariff relief.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
                 <p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
<br/>
<br/>
<strong>Excellence in Action</strong>
<br/>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
Discover the Impact

             </div>

<p>Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and supporting continued investment in manufacturing, and research and development in the US.</p>

Novartis, US government reach agreement to lower drug prices